Share results from first SP-26 animal study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 2 Jan 2025
- Due
- 30 Jun 2025
- Delivered
- 30 Apr 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we expect to share these results in early 2025”
What we found
Evidence strength B What the grades mean
Silo Pharma shared initial SP-26 animal study results in February 2025 and complete/final results on April 30, 2025, within the stated early-2025 window.
-
B Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 Initial animal study results announced; final data projected March 2025.
-
B Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study Final preclinical study results announced; all endpoints met.
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Share
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second checkThe evidence document could not be read for a second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Silo Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SILO-000009 · Corrections policy